An α1-adrenoceptor antagonist with only weak antagonism at post-junctional α2 receptors; a potent, persistent antihypertensive and vasodilator.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 428.96. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.33 mL||11.66 mL||23.31 mL|
|5 mM||0.47 mL||2.33 mL||4.66 mL|
|10 mM||0.23 mL||1.17 mL||2.33 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
References are publications that support the products' biological activity.
Borbe and Peter (1990) Alpha-1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. Arzneimittelforschung 40 253 PMID: 1971750
Muramatsu et al (1991) Pharmacological profile of the novel alpha-adrenoceptor antagonist KT-611 (naftopidil). Jpn.J.Pharmacol. 55 391 PMID: 1677438
If you know of a relevant reference for Naftopidil hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Naftopidil hydrochloride, supplier, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenoceptor, antagonists, α1-adrenergic, alpha1-adrenergic, a1-adrenergic, Receptors, Adrenergic, Alpha-1, Receptors, Adrenergic, Alpha-1, Receptors, Tocris Bioscience
Citations for Naftopidil hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Naftopidil hydrochloride. Do you know of a great paper that uses Naftopidil hydrochloride from Tocris? If so please let us know.
Naftopidil hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.